8-K Announcements
6Material company update
Feb 26, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Oct 16, 2025·SEC
Zai Lab Limited(ZLAB)Earnings, Financials & Key Ratios
ZLAB•NASDAQ
$21.01
$2.32B mkt cap·Price updated May 6, 2026
AboutZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.Show more
- Revenue$460M+15.3%
- EBITDA-$214M+18.1%
- Net Income-$176M+31.7%
- EPS (Diluted)-1.60+38.5%
- Gross Margin58.6%-6.9%
- EBITDA Margin-46.6%+29.0%
- Operating Margin-49.86%+29.5%
- Net Margin-38.15%+40.8%
- ROE-22.56%+28.2%
- ROIC-42.76%+42.8%
- Debt/Equity0.31+71.7%
- Interest Coverage-33.26+70.6%
ZLAB Key Insights
Zai Lab Limited (ZLAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 56.5%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ZLAB Price & Volume
Zai Lab Limited (ZLAB) stock price & volume — 10-year historical chart
Loading chart...
ZLAB Growth Metrics
Zai Lab Limited (ZLAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.54%
3 Years28.86%
TTM15.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.44%
Return on Capital
10 Years-46.93%
5 Years-36.99%
3 Years-33.02%
Last Year-27.94%
ZLAB Recent Earnings
Zai Lab Limited (ZLAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026EPS
$0.46
Est $0.44
-4.5%
Revenue
$128M
Est $122M
+4.4%
Q4 2025
Nov 6, 2025EPS
$0.33
Est $0.28
-17.9%
Revenue
$116M
Est $127M
-8.4%
Q3 2025
Aug 7, 2025EPS
$0.37
Est $0.37
+0.0%
Revenue
$110M
Est $150M
-26.8%
Q2 2025
May 8, 2025EPS
$0.45
Est $0.50
+10.0%
Revenue
$106M
Est $128M
-16.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.46vs $0.44-4.5% | $128Mvs $122M+4.4% |
| Q4 2025 | Nov 6, 2025 | $0.33vs $0.28-17.9% | $116Mvs $127M-8.4% |
| Q3 2025 | Aug 7, 2025 | $0.37vs $0.37+0.0% | $110Mvs $150M-26.8% |
| Q2 2025 | May 8, 2025 | $0.45vs $0.50+10.0% | $106Mvs $128M-16.5% |
Based on last 12 quarters of dataView full earnings history →
ZLAB Peer Comparison
Zai Lab Limited (ZLAB) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LEGN | 5.35B | 28.96 | -8.99 | 64.47% | -28.83% | -29.22% | 0.41 | |
 ZYME | 2.05B | 27.61 | -25.56 | 38.87% | -76.56% | -26% | 0.07 | |
 CAN | 355.58M | 0.55 | -1.23 | 96.69% | -39.68% | -48.08% | 0.13 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% |
Compare ZLAB vs Peers
Zai Lab Limited (ZLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZLAB Income Statement
Zai Lab Limited (ZLAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 129.45K | 12.98M | 48.96M | 144.31M | 215.04M | 266.72M | 398.99M | 460.16M |
| Revenue Growth % | - | - | 9930.55% | 277.04% | 194.77% | 49.01% | 24.03% | 49.59% | 15.33% |
| Cost of Goods Sold | 0 | 43.59K | 3.75M | 239.45M | 52.24M | 74.02M | 95.82M | 147.86M | 190.52M |
| COGS % of Revenue | - | 33.67% | 28.87% | 489.09% | 36.2% | 34.42% | 35.92% | 37.06% | 41.4% |
| Gross Profit | 0▲ 0% | 85.86K▲ 0% | 9.24M▲ 10656.7% | -190.49M▼ 2162.5% | 92.07M▲ 148.3% | 141.02M▲ 53.2% | 170.9M▲ 21.2% | 251.13M▲ 46.9% | 269.64M▲ 7.4% |
| Gross Margin % | - | 66.33% | 71.13% | -389.09% | 63.8% | 65.58% | 64.08% | 62.94% | 58.6% |
| Gross Profit Growth % | - | - | 10656.73% | -2162.47% | 148.34% | 53.16% | 21.19% | 46.94% | 7.37% |
| Operating Expenses | 51.39M | 141.85M | 212.43M | 111.31M | 792.14M | 545.38M | 537.48M | 533.25M | 498.51M |
| OpEx % of Revenue | - | 109580.34% | 1636.01% | 227.36% | 548.91% | 253.62% | 201.51% | 133.65% | 108.33% |
| Selling, General & Admin | 12.05M | 21.58M | 70.21M | 111.31M | 218.83M | 258.97M | 281.61M | 298.74M | 277.61M |
| SG&A % of Revenue | - | 16667.12% | 540.72% | 227.36% | 151.64% | 120.43% | 105.58% | 74.87% | 60.33% |
| Research & Development | 39.34M | 120.28M | 142.22M | 222.71M | 573.31M | 286.41M | 265.87M | 234.5M | 220.9M |
| R&D % of Revenue | - | 92913.22% | 1095.29% | 454.9% | 397.27% | 133.19% | 99.68% | 58.77% | 48.01% |
| Other Operating Expenses | 0 | 58.78K | 0 | -222.71M | 0 | 0 | -10M | 0 | 0 |
| Operating Income | -51.39M▲ 0% | -141.77M▼ 175.9% | -203.2M▼ 43.3% | -301.8M▼ 48.5% | -700.06M▼ 132.0% | -404.36M▲ 42.2% | -366.57M▲ 9.3% | -282.12M▲ 23.0% | -229.43M▲ 18.7% |
| Operating Margin % | - | -109514.01% | -1564.88% | -616.45% | -485.1% | -188.04% | -137.44% | -70.71% | -49.86% |
| Operating Income Growth % | -33.38% | -175.86% | -43.33% | -48.53% | -131.96% | 42.24% | 9.34% | 23.04% | 18.67% |
| EBITDA | -50.84M | -140.12M | -199.43M | -297.16M | -693.58M | -396.13M | -357.54M | -261.84M | -214.42M |
| EBITDA Margin % | - | -108239.58% | -1535.88% | -606.97% | -480.61% | -184.21% | -134.05% | -65.63% | -46.6% |
| EBITDA Growth % | -32.64% | -175.59% | -42.33% | -49.01% | -133.4% | 42.89% | 9.74% | 26.77% | 18.11% |
| D&A (Non-Cash Add-back) | 548K | 1.65M | 3.77M | 4.64M | 6.49M | 8.23M | 9.03M | 20.27M | 15.01M |
| EBIT | -51.39M | -138.45M | -194.03M | -301.8M | -695.95M | -443.06M | -374.14M | -254.85M | -173.25M |
| Net Interest Income | 0 | 3.22M | 7.94M | 4.94M | 2.19M | 14.58M | 39.8M | 34.85M | 27.84M |
| Interest Income | 527.35K | 3.26M | 8.23M | 5.12M | 2.19M | 14.58M | 39.8M | 37.1M | 33.05M |
| Interest Expense | 0 | 39.67K | 293K | 181K | 0 | 0 | 0 | 2.25M | 5.21M |
| Other Income/Expense | 1.01M | 3.28M | -2.83M | 32.9M | -3.35M | -38.93M | 31.95M | 25.01M | 50.97M |
| Pretax Income | -50.13M▲ 0% | -138.49M▼ 176.2% | -206.02M▼ 48.8% | -268.9M▼ 30.5% | -703.41M▼ 161.6% | -443.29M▲ 37.0% | -334.62M▲ 24.5% | -257.1M▲ 23.2% | -178.46M▲ 30.6% |
| Pretax Margin % | - | -106980.46% | -1586.66% | -549.26% | -487.43% | -206.14% | -125.46% | -64.44% | -38.78% |
| Income Tax | 477.7K | 3.32M | -10.95M | 0 | 1.06M | 0 | 0 | 0 | -2.93M |
| Effective Tax Rate % | -0.95% | -2.4% | 5.32% | 0% | -0.15% | 0% | 0% | 0% | 1.64% |
| Net Income | -50.38M▲ 0% | -139.07M▼ 176.0% | -195.07M▼ 40.3% | -268.9M▼ 37.8% | -704.47M▼ 162.0% | -443.29M▲ 37.1% | -334.62M▲ 24.5% | -257.1M▲ 23.2% | -175.54M▲ 31.7% |
| Net Margin % | - | -107433.56% | -1502.31% | -549.26% | -488.16% | -206.14% | -125.46% | -64.44% | -38.15% |
| Net Income Growth % | -34.31% | -176.03% | -40.26% | -37.85% | -161.98% | 37.08% | 24.51% | 23.17% | 31.72% |
| Net Income (Continuing) | -50.38M | -139.07M | -195.07M | -268.9M | -704.47M | -443.29M | -334.62M | -257.1M | -175.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -23.20▲ 0% | -26.40▼ 13.8% | -30.30▼ 14.8% | -34.60▼ 14.2% | -75.80▼ 119.1% | -46.30▲ 38.9% | -34.60▲ 25.3% | -2.60▲ 92.5% | -1.60▲ 38.5% |
| EPS Growth % | 41.56% | -13.79% | -14.77% | -14.19% | -119.08% | 38.92% | 25.27% | 92.49% | 38.46% |
| EPS (Basic) | -23.20 | -26.40 | -30.30 | -34.60 | -75.80 | -46.30 | -34.60 | -2.60 | -1.60 |
| Diluted Shares Outstanding | 2.18M | 5.26M | 6.44M | 7.77M | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
| Basic Shares Outstanding | 2.18M | 5.26M | 6.44M | 7.77M | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ZLAB Balance Sheet
Zai Lab Limited (ZLAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 230.61M | 269.14M | 292.46M | 1.22B | 1.5B | 1.12B | 939.61M | 1.05B | 1.02B |
| Cash & Short-Term Investments | 229.66M | 263.3M | 275.93M | 1.19B | 1.41B | 1.01B | 806.45M | 779.67M | 689.57M |
| Cash Only | 229.66M | 62.95M | 75.93M | 442.12M | 964.1M | 1.01B | 790.15M | 449.67M | 679.57M |
| Short-Term Investments | 0 | 200.35M | 200M | 744.68M | 445M | 0 | 16.3M | 330M | 10M |
| Accounts Receivable | 0 | 90K | 3.79M | 5.17M | 54.81M | 48.57M | 65.33M | 89.41M | 106.12M |
| Days Sales Outstanding | - | 253.76 | 106.56 | 38.51 | 138.63 | 82.44 | 89.41 | 81.79 | 84.17 |
| Inventory | 0 | 3.82K | 6M | 13.14M | 18.95M | 31.62M | 44.83M | 39.88M | 74.75M |
| Days Inventory Outstanding | - | 32 | 584.67 | 20.04 | 132.41 | 155.93 | 170.76 | 98.43 | 143.2 |
| Other Current Assets | 0 | -603 | 0 | 0 | 0 | 35.67M | 23M | 141.53M | 148.85M |
| Total Non-Current Assets | 19.02M | 32.84M | 62.69M | 81.6M | 109.08M | 95.8M | 96.69M | 135.27M | 153.1M |
| Property, Plant & Equipment | 11.98M | 20.77M | 36.86M | 47.14M | 58.28M | 78.77M | 68.69M | 69.47M | 66.54M |
| Fixed Asset Turnover | - | 0.01x | 0.35x | 1.04x | 2.48x | 2.73x | 3.88x | 5.74x | 6.92x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 20.09K | 321.57K | 8.8M | 9.44M | 9.66M | 8.4M | 16.46M | 58.93M | 76.14M |
| Long-Term Investments | 1.65M | 3.15M | 2.4M | 1.28M | 15.61M | 6.43M | 9.22M | 3.12M | 0 |
| Other Non-Current Assets | 5.5M | 8.88M | 14.62M | 23.75M | 25.53M | 2.2M | 2.32M | 3.75M | 7.02M |
| Total Assets | 249.63M▲ 0% | 301.99M▲ 21.0% | 355.15M▲ 17.6% | 1.3B▲ 265.4% | 1.61B▲ 24.1% | 1.22B▼ 24.2% | 1.04B▼ 15.1% | 1.19B▲ 14.4% | 1.17B▼ 1.1% |
| Asset Turnover | - | 0.00x | 0.04x | 0.04x | 0.09x | 0.18x | 0.26x | 0.34x | 0.39x |
| Asset Growth % | 180.78% | 20.97% | 17.61% | 265.37% | 24.07% | -24.21% | -15.07% | 14.42% | -1.13% |
| Total Current Liabilities | 12.07M | 48.84M | 46.63M | 98.04M | 192.9M | 139.84M | 203.07M | 299.38M | 416.17M |
| Accounts Payable | 8.97M | 37.43M | 22.66M | 62.64M | 126.16M | 65.97M | 112.99M | 100.91M | 141.61M |
| Days Payables Outstanding | - | 313.44K | 2.21K | 95.49 | 881.52 | 325.33 | 430.43 | 249.09 | 271.29 |
| Short-Term Debt | 0 | 3.64M | 6.45M | 0 | 0 | 0 | 0 | 131.71M | 210.87M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.33M |
| Other Current Liabilities | 778.96K | 2.5M | 2.39M | 4.57M | 4.42M | 4.05M | 5.35M | 6.35M | 36.35M |
| Current Ratio | 19.11x | 5.51x | 6.27x | 12.40x | 7.78x | 8.04x | 4.63x | 3.51x | 2.45x |
| Quick Ratio | 19.11x | 5.51x | 6.14x | 12.27x | 7.68x | 7.81x | 4.41x | 3.38x | 2.27x |
| Cash Conversion Cycle | - | -313.15K | -1.52K | -36.94 | -610.48 | -86.96 | -170.26 | -68.86 | -43.92 |
| Total Non-Current Liabilities | 2.39M | 2.06M | 13.86M | 30.25M | 37.1M | 34.7M | 37.11M | 45.47M | 40.72M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.38M |
| Capital Lease Obligations | 0 | 0 | 10.98M | 13.39M | 9.61M | 13.34M | 8.05M | 13.71M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 325K | 325K | 27.33M |
| Total Liabilities | 14.46M | 50.91M | 60.49M | 128.29M | 230M | 174.54M | 240.18M | 344.86M | 456.88M |
| Total Debt | 0 | 3.64M | 21.78M | 18.6M | 15.54M | 20.39M | 15.15M | 153.47M | 224.26M |
| Net Debt | -229.66M | -59.31M | -54.15M | -423.52M | -948.56M | -988.08M | -775M | -296.2M | -455.31M |
| Debt / Equity | - | 0.01x | 0.07x | 0.02x | 0.01x | 0.02x | 0.02x | 0.18x | 0.31x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -3489.82x | -662.20x | -1667.41x | - | - | - | -113.07x | -33.26x |
| Total Equity | 235.17M▲ 0% | 251.08M▲ 6.8% | 294.66M▲ 17.4% | 1.17B▲ 296.8% | 1.38B▲ 18.0% | 1.05B▼ 24.2% | 796.12M▼ 23.9% | 840.9M▲ 5.6% | 715.5M▼ 14.9% |
| Equity Growth % | 556.18% | 6.77% | 17.36% | 296.85% | 18.01% | -24.23% | -23.86% | 5.62% | -14.91% |
| Book Value per Share | 108.11 | 47.73 | 45.78 | 150.56 | 148.39 | 109.14 | 82.38 | 8.50 | 6.53 |
| Total Shareholders' Equity | 235.17M | 251.08M | 294.66M | 1.17B | 1.38B | 1.05B | 796.12M | 840.9M | 715.5M |
| Common Stock | 3K | 3.48K | 4K | 5K | 6K | 6K | 6K | 7K | 7K |
| Retained Earnings | -110.55M | -249.63M | -444.7M | -713.6M | -1.42B | -1.86B | -2.2B | -2.45B | -2.63B |
| Treasury Stock | 0 | 0 | 0 | 0 | -4.28M | -11.86M | -20.84M | -20.84M | 0 |
| Accumulated OCI | 449.91K | 2.66M | 4.62M | -14.52M | -23.64M | 25.68M | 37.63M | 50.52M | 29.7M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZLAB Cash Flow Statement
Zai Lab Limited (ZLAB) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -32.37M | -97.54M | -191.01M | -216.06M | -549.23M | -367.64M | -198.18M | -214.87M | -150.79M |
| Operating CF Margin % | - | -75346.86% | -1471.04% | -441.31% | -380.59% | -170.96% | -74.3% | -53.85% | -32.77% |
| Operating CF Growth % | -0.65% | -201.35% | -95.83% | -13.11% | -154.21% | 33.06% | 46.09% | -8.42% | 29.82% |
| Net Income | -50.38M | -139.07M | -195.07M | -268.9M | -704.47M | -443.29M | -334.62M | -257.1M | -175.54M |
| Depreciation & Amortization | 548.13K | 1.65M | 3.77M | 4.64M | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| Stock-Based Compensation | 9.93M | 12.23M | 20.29M | 24.83M | 40.71M | 61.3M | 79.63M | 70.65M | 65.6M |
| Deferred Taxes | 0 | 587.25K | 767K | 1.13M | 17.08M | 0 | 0 | 0 | -3.34M |
| Other Non-Cash Items | 62.61K | -312K | 2.52M | 4.01M | 67.85M | 72.36M | 8.17M | 28.12M | -1.02M |
| Working Capital Changes | 7.48M | 27.38M | -23.28M | 18.25M | 23.11M | -66.25M | 39.61M | -68.39M | -51.51M |
| Change in Receivables | 0 | -89.71K | -3.7M | -1.38M | -42.32M | 25.14M | -17.69M | -26.58M | -26.72M |
| Change in Inventory | 0 | -3.82K | -6M | -7.17M | -7.17M | -15.38M | -14.91M | 3.9M | -47.15M |
| Change in Payables | 8.44M | 28.46M | -14.77M | 39.98M | 63.52M | -53.77M | 36.8M | -2.21M | 19.93M |
| Cash from Investing | -10.43M | -212.55M | -14.89M | -554.83M | 249.96M | 420.02M | -10.78M | -375.19M | 307.87M |
| Capital Expenditures | -9.12M | -10.12M | -15.24M | -10.67M | -18.95M | -24.59M | -7.21M | -5.66M | -8.1M |
| CapEx % of Revenue | - | 7815.9% | 117.38% | 21.79% | 13.13% | 11.43% | 2.7% | 1.42% | 1.76% |
| Acquisitions | -1.9M | -2.09M | 9.21M | 539K | -30M | 0 | 0 | 29K | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 68.1K | -102.83K | -9.21M | -539K | 3K | -399K | 12.74M | -55.86M | -5.24M |
| Cash from Financing | 187.86M | 144.15M | 219.3M | 1.13B | 820.2M | -1.73M | -6.43M | 349.89M | 72.35M |
| Debt Issued (Net) | 0 | 3.64M | 2.9M | -6.53M | 0 | 0 | 0 | 131.32M | 68.12M |
| Equity Issued (Net) | 189.53M | 141M | 216.2M | 1.14B | 818.88M | 0 | 0 | 217.35M | 12.85M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.67M | -496.2K | 201K | 1.28M | 1.33M | -1.73M | -6.43M | 1.22M | -8.63M |
| Net Change in Cash | 145.71M▲ 0% | -166.71M▼ 214.4% | 13.49M▲ 108.1% | 366.42M▲ 2616.2% | 522.04M▲ 42.5% | 44.37M▼ 91.5% | -218.01M▼ 591.3% | -240.48M▼ 10.3% | 229.91M▲ 195.6% |
| Free Cash Flow | -41.48M▲ 0% | -107.66M▼ 159.5% | -206.25M▼ 91.6% | -226.72M▼ 9.9% | -568.18M▼ 150.6% | -392.63M▲ 30.9% | -206.67M▲ 47.4% | -276.39M▼ 33.7% | -158.89M▲ 42.5% |
| FCF Margin % | - | -83162.76% | -1588.42% | -463.1% | -393.72% | -182.58% | -77.49% | -69.27% | -34.53% |
| FCF Growth % | -20.64% | -159.51% | -91.59% | -9.93% | -150.6% | 30.9% | 47.36% | -33.74% | 42.51% |
| FCF per Share | -19.07 | -20.46 | -32.04 | -29.19 | -61.10 | -40.98 | -21.39 | -2.79 | -1.45 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.70x | 0.98x | 0.80x | 0.78x | 0.83x | 0.59x | 0.84x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.02M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZLAB Key Ratios
Zai Lab Limited (ZLAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -54.88% | -57.2% | -71.49% | -36.74% | -55.27% | -36.55% | -36.34% | -31.41% | -22.56% |
| Return on Invested Capital (ROIC) | - | -699.41% | -107.79% | -70.51% | -45.9% | -89.2% | -124.06% | -699.25% | -74.79% | -42.76% |
| Gross Margin | - | - | 66.33% | 71.13% | -389.09% | 63.8% | 65.58% | 64.08% | 62.94% | 58.6% |
| Net Margin | - | - | -107433.56% | -1502.31% | -549.26% | -488.16% | -206.14% | -125.46% | -64.44% | -38.15% |
| Debt / Equity | - | - | 0.01x | 0.07x | 0.02x | 0.01x | 0.02x | 0.02x | 0.18x | 0.31x |
| Interest Coverage | - | - | -3489.82x | -662.20x | -1667.41x | - | - | - | -113.07x | -33.26x |
| FCF Conversion | 0.86x | 0.64x | 0.70x | 0.98x | 0.80x | 0.78x | 0.83x | 0.59x | 0.84x | 0.86x |
| Revenue Growth | - | - | - | 9930.55% | 277.04% | 194.77% | 49.01% | 24.03% | 49.59% | 15.33% |
ZLAB SEC Filings & Documents
Zai Lab Limited (ZLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZLAB Frequently Asked Questions
Zai Lab Limited (ZLAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zai Lab Limited (ZLAB) reported $460.2M in revenue for fiscal year 2025.
Zai Lab Limited (ZLAB) grew revenue by 15.3% over the past year. This is strong growth.
Zai Lab Limited (ZLAB) reported a net loss of $175.5M for fiscal year 2025.
Dividend & Returns
Zai Lab Limited (ZLAB) has a return on equity (ROE) of -22.6%. Negative ROE indicates the company is unprofitable.
Zai Lab Limited (ZLAB) had negative free cash flow of $158.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More ZLAB
Zai Lab Limited (ZLAB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates